Which is better, CON or IDXX?

On the Buffett-Fit framework, IDEXX Laboratories, Inc. (IDXX) currently grades higher than CON — 75/100 (B grade) vs 62/100 (C). That said, "better" depends on which framework you trust — CON wins on none; IDXX wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy CON or IDXX?

This page is an educational comparison, not investment advice. Both CON and IDXX are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is CON better than IDXX for value investing?

On the Buffett-style value-investing framework, IDXX currently grades higher — 75/100 vs 62/100, a 13-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between CON and IDXX on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). CON currently scores 62/100 (C grade); IDXX scores 75/100 (B grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, CON or IDXX?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. CON and IDXX are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, CON or IDXX?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are CON and IDXX both Healthcare stocks?

Yes — both Concentra Group Holdings Parent, Inc. (CON) and IDEXX Laboratories, Inc. (IDXX) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this CON vs IDXX comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Concentra Group Holdings Parent

IDEXX Laboratories

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

CON

Market cap

$3.24B

Sector

Healthcare

IDXX

IDEXX Laboratories

Market cap

$44.12B

Sector

Healthcare

Overall winner

IDEXX Laboratories IDXX

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	CON	IDXX	Winner
Warren Buffett	62C	75B	IDXX
Benjamin Graham	78B	80A	IDXX
Philip Fisher	39D	75B	IDXX
Peter Lynch	37D	71B	IDXX
Joel Greenblatt	55C	83C	IDXX
Charlie Munger	67C	87A	IDXX
Terry Smith	66C	84A	IDXX

Side-by-side metrics

Metric	CON	IDXX
Market cap	$3.24B	$44.12B
P/E (TTM)	18.6x	39.0x
EV/EBIT	2.6x	31.6x
ROIC (TTM)	60.75%	40.66%
Gross margin	27.79%	62.05%
Net margin	7.97%	24.63%
Revenue CAGR 5y	5.72%	7.56%
EPS CAGR 5y	-4.2%	10.79%
Debt / Equity	5.0x	0.7x
Dividend yield	0.96%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

CON leads on

Dividend yield0.96%vs 0.0%+100%
EV/EBIT2.6xvs 31.6x+92%
P/E (TTM)18.6xvs 39.0x+52%
ROIC (TTM)60.75%vs 40.66%+33%

IDXX leads on

EPS CAGR 5y10.79%vs -4.2%+139%
Market cap$44.12Bvs $3.24B+93%
Debt / Equity0.7xvs 5.0x+86%
Net margin24.63%vs 7.97%+68%

More like CON

CON vs 7741.T CON vs GMAB CON vs SUNPHARMA.NS CON vs LMAT CON vs HALO CON vs MTD

More like IDXX

IDXX vs 7741.T IDXX vs GMAB IDXX vs SUNPHARMA.NS IDXX vs LMAT IDXX vs HALO IDXX vs MTD

Read the full Buffett-Brain analysis for CON Read the full Buffett-Brain analysis for IDXX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

Concentra Group Holdings Parent

IDEXX Laboratories

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

CON

Concentra Group Holdings Parent

Market cap

$3.24B

Sector

Healthcare

IDXX

IDEXX Laboratories

Market cap

$44.12B

Sector

Healthcare

Overall winner

IDEXX Laboratories IDXX

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	CON	IDXX	Winner
Warren Buffett	62C	75B	IDXX
Benjamin Graham	78B	80A	IDXX
Philip Fisher	39D	75B	IDXX
Peter Lynch	37D	71B	IDXX
Joel Greenblatt	55C	83C	IDXX
Charlie Munger	67C	87A	IDXX
Terry Smith	66C	84A	IDXX

Side-by-side metrics

Metric	CON	IDXX
Market cap	$3.24B	$44.12B
P/E (TTM)	18.6x	39.0x
EV/EBIT	2.6x	31.6x
ROIC (TTM)	60.75%	40.66%
Gross margin	27.79%	62.05%
Net margin	7.97%	24.63%
Revenue CAGR 5y	5.72%	7.56%
EPS CAGR 5y	-4.2%	10.79%
Debt / Equity	5.0x	0.7x
Dividend yield	0.96%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

CON leads on

Dividend yield0.96%vs 0.0%+100%
EV/EBIT2.6xvs 31.6x+92%
P/E (TTM)18.6xvs 39.0x+52%
ROIC (TTM)60.75%vs 40.66%+33%

IDXX leads on

EPS CAGR 5y10.79%vs -4.2%+139%
Market cap$44.12Bvs $3.24B+93%
Debt / Equity0.7xvs 5.0x+86%
Net margin24.63%vs 7.97%+68%

More like CON

CON vs 7741.T CON vs GMAB CON vs SUNPHARMA.NS CON vs LMAT CON vs HALO CON vs MTD

More like IDXX

IDXX vs 7741.T IDXX vs GMAB IDXX vs SUNPHARMA.NS IDXX vs LMAT IDXX vs HALO IDXX vs MTD

Read the full Buffett-Brain analysis for CON Read the full Buffett-Brain analysis for IDXX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.